In short
Datopotamab Deruxtecan (Dato-DXd) is an innovative antibody-drug conjugate being studied in clinical trials for various advanced cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. This article explores the ongoing research into Dato-DXd's efficacy and safety as a potential treatment option for patients with limited alternatives.
At a glance
- Drug Name
- Datopotamab Deruxtecan (Dato-DXd)
- Drug Type
- Antibody-drug conjugate (ADC)
- Target
- TROP2 protein on cancer cells
- Main Cancer Types Studied
- Non-small cell lung cancer (NSCLC), Metastatic breast cancer (HER2-low, Triple-negative)
- Key Clinical Trials
- TROPION-Lung08, TROPION-Lung10, DATO-BASE, TRADE DXd
- Administration
- Intravenous infusion, typically 6 mg/kg every 3 weeks
- Combination Therapies
- Pembrolizumab, Carboplatin, Rilvegostomig
- Primary Outcomes Measured
- Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS)
- Special Populations
- Patients with brain metastases
- Current Status
- Investigational; not yet FDA-approved for most indications
Introduction
Datopotamab deruxtecan is an innovative cancer treatment currently being studied in clinical trials. It's a type of drug called an antibody-drug conjugate (ADC), which combines a targeted antibody with a potent chemotherapy drug. This medication is also known by other names, including Dato-DXd and DS-1062a.
How Datopotamab Deruxtecan Works
Datopotamab deruxtecan works by targeting a specific protein called TROP2, which is found in high amounts on many cancer cells. The antibody part of the drug attaches to TROP2 on cancer cells. Then, the drug is taken into the cell where it releases a powerful chemotherapy agent. This targeted approach aims to kill cancer cells while minimizing damage to healthy cells.
Conditions Treated
Datopotamab deruxtecan is being studied for several types of cancer, including:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Datopotamab deruxtecan is being tested in patients with advanced or metastatic NSCLC, including those whose cancer has spread to the brain.
- Breast cancer: Studies are looking at its effectiveness in different types of breast cancer, including HER2-negative and triple-negative breast cancers, especially when the cancer has spread to the brain.
Current Clinical Trials
Several clinical trials are currently underway to test datopotamab deruxtecan:
- NSCLC with brain metastases: A phase II trial is studying how well the drug works in patients whose lung cancer has spread to the brain.
- Breast cancer with brain metastases: Multiple studies are looking at its effectiveness in different types of breast cancer that have spread to the brain.
- Combination therapy: A large phase III trial is comparing the combination of datopotamab deruxtecan with another drug called osimertinib to osimertinib alone in patients with certain types of NSCLC.
How It's Administered
Datopotamab deruxtecan is given as an intravenous (IV) infusion, typically once every three weeks. The dose is usually calculated based on the patient's body weight. For example, one common dosage is 6 mg/kg (6 milligrams for every kilogram of body weight).
Potential Side Effects
As with any cancer treatment, datopotamab deruxtecan can cause side effects. While specific side effects are still being studied in clinical trials, some potential side effects may include:
- Nausea and vomiting
- Mouth sores (stomatitis)
- Infusion-related reactions
- Eye problems
Doctors often prescribe medications to help prevent or manage these side effects. It's important to discuss potential side effects with your healthcare team.
Frequently Asked Questions
Is datopotamab deruxtecan approved for use?
As of now, datopotamab deruxtecan is not yet approved by the FDA. It's still being studied in clinical trials to determine its safety and effectiveness.
How long can I receive datopotamab deruxtecan treatment?
In clinical trials, patients typically receive the treatment until their disease progresses, they experience unacceptable side effects, or they choose to discontinue. The exact duration can vary for each patient.
Can I participate in a clinical trial for datopotamab deruxtecan?
Eligibility for clinical trials depends on various factors, including your specific type of cancer, previous treatments, and overall health. Speak with your oncologist about whether you might be eligible for any ongoing trials.
Summary
| Aspect | Details |
|---|---|
| Drug Type | Antibody-drug conjugate (ADC) |
| Target | TROP2 protein on cancer cells |
| Conditions Studied | NSCLC, Breast Cancer (especially with brain metastases) |
| Administration | Intravenous infusion, typically every 3 weeks |
| Current Status | In clinical trials, not yet FDA approved |
Glossary
- Antibody-drug conjugate (ADC) - A type of cancer treatment that combines a targeted antibody with a chemotherapy drug
- TROP2 - A protein found in high amounts on many cancer cells
- Non-small cell lung cancer (NSCLC) - The most common type of lung cancer
- Metastases - Areas where cancer has spread to other parts of the body
- HER2-negative - A type of breast cancer that doesn't have high levels of a protein called HER2
- Triple-negative breast cancer - A type of breast cancer that doesn't have receptors for estrogen, progesterone, or HER2